Cipla gets nod to invest upto $100 million in Cipla (EU)
The board at its meeting held on March 19, 2026 has approved the same
Cipla has received approval from board of directors for investment upto $100 million in the equity share capital of Cipla (EU), a wholly- owned subsidiary of the Company for the purpose of providing onward financial assistance to InvaGen Pharmaceuticals Inc., wholly-owned subsidiary of Cipla (EU), to meet its capital expenditure, working capital requirements and other general corporate purposes.
The board at its meeting held on March 19, 2026 has approved the same.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
